Citius Pharmaceuticals (CTXR) Accumulated Expenses (2011 - 2026)
Citius Pharmaceuticals' (CTXR) quarterly Accumulated Expenses came in at $4.1 million in Q1 2026, down 53.73% YoY from $8.8 million in Q1 2025, and down 13.44% on a QoQ basis from $4.7 million in Q4 2025.
Citius Pharmaceuticals (CTXR) Accumulated Expenses (2011 - 2026) Analysis & Trends
Citius Pharmaceuticals (CTXR) has 16 years of Accumulated Expenses data on file, last reported at $4.1 million in Q1 2026.
- Quarterly Accumulated Expenses fell 53.73% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 53.73% YoY) and the FY2025 annual result came in at $4.2 million, up 24509.46% from the prior year.
- Accumulated Expenses declined to $4.1 million in Q1 2026, from $4.7 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $8.8 million in Q1 2025 to a low of $17027.0 in Q3 2024.
- A 5-year average of $2.9 million and a median of $1.8 million in 2022 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses soared 65816.87% — and 2024, when it plunged 96.43%.
- Tracing CTXR's Accumulated Expenses over 5 years: stood at $2.1 million in 2022, then rose by 15.36% to $2.4 million in 2023, then soared by 156.81% to $6.2 million in 2024, then declined by 24.81% to $4.7 million in 2025, then dropped by 13.44% to $4.1 million in 2026.
- The last three Accumulated Expenses figures came in at $4.1 million (Q1 2026), $4.7 million (Q4 2025), and $4.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Citius Pharmaceuticals | 15.71 Mn | 15.71 Mn | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.06 Mn |
| Dec 31, 2025 | 4.69 Mn |
| Sep 30, 2025 | 4.19 Mn |
| Jun 30, 2025 | 8.52 Mn |
| Mar 31, 2025 | 8.78 Mn |
| Dec 31, 2024 | 6.24 Mn |
| Sep 30, 2024 | 17,027.00 |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 151,204.00 |
| Dec 31, 2023 | 2.43 Mn |
| Sep 30, 2023 | 476,300.00 |
| Jun 30, 2023 | 1.61 Mn |
| Mar 31, 2023 | 1.03 Mn |
| Dec 31, 2022 | 2.11 Mn |
| Sep 30, 2022 | 1.76 Mn |
| Jun 30, 2022 | 1.30 Mn |
| Mar 31, 2022 | 793,250.00 |
| Dec 31, 2021 | 3.14 Mn |
| Sep 30, 2021 | 1.91 Mn |
| Jun 30, 2021 | 1,974.00 |